SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BMY (bristol myers squibb)
BMY 42.64-0.4%Oct 29 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (127)1/21/2018 11:26:09 AM
From: Miljenko Zuanic  Read Replies (1) of 194
 
What kind of F-ing SHIT is this:
<The Opdivo plus Yervoy combination cohort included 119 patients with a median follow-up of 13.4 months. At the time of data cutoff (July 2017) median PFS was not yet reached, the 12-month PFS rate was 71% (95% CI: 61.4 to 78.7) and the rate of disease control lasting at least 12 weeks was 80%. Investigator-assessed responses were observed irrespective of tumor BRAF or KRAS mutation status, tumor PD-L1 expression or clinical history of Lynch syndrome. >


https://finance.yahoo.com/news/opdivo-nivolumab-combination-yervoy-ipilimumab-190300831.html


In 6 MONTHS they can not do update on results? What they are afraid off? Sometimes I do think that MRK is doing better job than BMY!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News